BioSpace News Archive

Cortexyme to Present at H.C. Wainwright 23rd Annual Global Investment Conference on September 13th

Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces it has commenced a collaboration with Kettering Health (KH), a faith-based network of 13 hospitals, emergency centers, and outpatient facilities located in Southwest Ohio; headquartered at the Kettering Memorial Hospital in Kettering, Ohio, United States.

Agilent Technologies Inc. (NYSE: A) today announced Dr. David R. Liu has been selected to receive a prestigious Agilent Thought Leader Award.

CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, today provided an update with respect to its resubmission timeline for the DefenCath New Drug Application (“NDA”).

Cocrystal Pharma, Inc announces that management will present at the 23rd Annual Global Investment Conference being held September 13-15, 2021. webcast of the presentation will be available on the IR Calendar of the Cocrystal Pharma website beginning at 1:00 a.m. Eastern time on Monday, September 13, 2021. “We look forward to discussing progress an

Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced a successful outcome from the Company’s Type A meeting with the U.S. Food and Drug Administration (FDA)

Alcresta Therapeutics, Inc. today announced that the Centers for Medicare & Medicaid Services (CMS) has published a Local Coverage Determination (LCD) on enteral nutrition (LCD ID No. 38955) that confirms coverage for RELiZORB® (immobilized lipase).

Inhibikase Therapeutics, Inc. today announced that Dr. Milton Werner , Ph.D., Chief Executive Officer of Inhibikase, will present at the H.C. Wainwright 23rd Annual Global Investment Conference, being held from September 13-15, 2021.

Poseida Therapeutics, Inc., a clinical-stage biopharmaceutical company utilizing proprietary genetic engineering platform technologies to create cell and gene therapeutics with the capacity to cure, announced that the Company will participate in the following upcoming virtual investor conferences.

Biocept, a leading provider of molecular diagnostic assays and services, announces that Michael Nall, President and CEO, will present at four upcoming investor conferences.